Skip to Main Content

Author Details

Heather N Reich
University Health Network and University of Toronto
2000
138
42
PMIDPaper TitleJournal TitlePublished Year
36509342Renal Thrombotic Microangiopathy: A Review.Am J Kidney Dis2023
37526679Prophylactic Anticoagulation in Nephrotic Syndrome.Kidney3602023
37591292Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.Lancet2023
37060902Metformin triggers a kidney GDF15-dependent area postrema axis to regulate food intake and body weight.Cell Metab2023
37349951Dynamics of urine proteomics biomarker and disease progression in patients with IgA nephropathy.Nephrol Dial Transplant2023
37337107Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy.Nat Genet2023
37471101Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy.Clin J Am Soc Nephrol2023
37263354IgA nephropathy: the lectin pathway and implications for targeted therapy.Kidney Int2023
36442540Precision nephrology identified tumor necrosis factor activation variability in minimal change disease and focal segmental glomerulosclerosis.Kidney Int2023
36805625CanVasc consensus recommendations for the use of avacopan in antineutrophil cytoplasm antibody-associated vasculitis: 2022 addendum.Rheumatology (Oxford)2023
35133979Immunoglobulin A nephropathy is characterized by anticommensal humoral immune responses.JCI Insight2022
35675911How I Treat IgA Nephropathy.Clin J Am Soc Nephrol2022
35579642Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.JAMA2022
35490842Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy.Kidney Int2022
35659570The Risk of Cardiovascular Events in Individuals With Primary Glomerular Diseases.Am J Kidney Dis2022
35450151The Canadian Glomerulonephritis Registry (CGNR) and Translational Research Initiative: Rationale and Clinical Research Protocol.Can J Kidney Health Dis2022
36506237One-Year estimated GFR Slope Independently Predicts Clinical Benefit in Immunoglobulin A Nephropathy.Kidney Int Rep2022
36531879Clinicopathologic Significance of Predominant Lambda Light Chain Deposition in IgA Nephropathy.Kidney Int Rep2022
36302105Vishma's story: a mystery solved.CMAJ2022
36090486Diagnosis and Treatment of Patients With Focal Segmental Glomerulosclerosis/Steroid-Resistant Nephrotic Syndrome: A Delphi Survey.Kidney Int Rep2022
36090484International Physicians Delphi Survey: Managing Patients With IgA Nephropathy.Kidney Int Rep2022
32934123CanVasc Consensus Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitis: 2020 Update.J Rheumatol2021
35368364Corticosteroids Should Be Used To Treat Slowly Progressive IgA Nephropathy: PRO.Kidney3602021
33851121Type IV Collagen Variants in CKD: Performance of Computational Predictions for Identifying Pathogenic Variants.Kidney Med2021
33514642Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy.J Am Soc Nephrol2021
33646395APOL1 genotype-associated morphologic changes among patients with focal segmental glomerulosclerosis.Pediatr Nephrol2021
33587286Evaluation of the Pharmacokinetics and Exposure-Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease.Clin Pharmacokinet2021
33928392Interpretation and Clinical Value of Serum Anti-PLA2R-Antibody Testing.J Appl Lab Med2021
35005315Efficacy of Rituximab in Treatment-Resistant Focal Segmental Glomerulosclerosis With Elevated Soluble Urokinase-Type Plasminogen Activator Receptor and Activation of Podocyte β3 Integrin.Kidney Int Rep2021
35005306How Should Pathology Findings Influence Treatment in IgA Nephropathy?Kidney Int Rep2021
34502419Follistatin-Like-1 (FSTL1) Is a Fibroblast-Derived Growth Factor That Contributes to Progression of Chronic Kidney Disease.Int J Mol Sci2021
34556300Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.Kidney Int2021
34731857The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics.Am J Nephrol2021
34664087The microbiome and IgA nephropathy.Semin Immunopathol2021
34247883IgA Nephropathy: Core Curriculum 2021.Am J Kidney Dis2021
33313853Urine proteomics for prediction of disease progression in patients with IgA nephropathy.Nephrol Dial Transplant2021
32559474Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.Lancet Diabetes Endocrinol2020
33163724Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy.Kidney Int Rep2020
33294202Management of Patients With Glomerulonephritis During the COVID-19 Pandemic: Recommendations From the Canadian Society of Nephrology COVID-19 Rapid Response Team.Can J Kidney Health Dis2020
32938443How to optimize the design and implementation of risk prediction tools: focus group with patients with IgA nephropathy.BMC Med Inform Decis Mak2020
32954090The Authors Reply.Kidney Int Rep2020
32464215Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool.Kidney Int2020
32405591Serum Albumin at Partial Remission Predicts Outcomes in Membranous Nephropathy.Kidney Int Rep2020
30635299Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy.Clin J Am Soc Nephrol2019
31759495The Case | Severe symptomatic hypocalcemia in a patient with sickle cell disease.Kidney Int2019
31639674What Is Really in This Weight Loss Supplement?J Appl Lab Med2019
32905199The longitudinal relationship between patient-reported outcomes and clinical characteristics among patients with focal segmental glomerulosclerosis in the Nephrotic Syndrome Study Network.Clin Kidney J2019
31269364Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.N Engl J Med2019
31547518Rethinking Lupus Nephritis Classification on a Molecular Level.J Clin Med2019
30980653Evaluating a New International Risk-Prediction Tool in IgA Nephropathy.JAMA Intern Med2019
  • 1 - 50 of 138

Recommended Authors

Dennis G Moledina
Yale School of Medicine
Career Start Year 2013
Number of shared co-authors 12
Anand Srivastava
Global Institute of Stem Cell Therapy and Research 4660 La Jolla Village Drive
Career Start Year 2012
Number of shared co-authors 6
Farrukh M Koraishy
Stony Brook University Hospital
Career Start Year 2011
Number of shared co-authors 1
Isabelle Ayoub
Wexner Medical Center, The Ohio State University
Career Start Year 2011
Number of shared co-authors 18
Luis M Ortega
Alegheny General Hospital, Temple University School of Medicine
Career Start Year 2009
Number of shared co-authors 0
Jennifer A Schaub
University of Michigan ann arbor
Career Start Year 2008
Number of shared co-authors 15
Jamie P Dwyer
University of Utah Health
Career Start Year 2005
Number of shared co-authors 1
Kelly V Liang
University of Pittsburgh
Career Start Year 2004
Number of shared co-authors 1
Martin H de Borst
University Medical Center Groningen
Career Start Year 2003
Number of shared co-authors 7
Mark S Segal
University of Florida
Career Start Year 2001
Number of shared co-authors 1
Sandeep K Mallipattu
Stony Brook School of Medicine
Career Start Year 2001
Number of shared co-authors 1
Serhan Tuglular
Marmara University
Career Start Year 1999
Number of shared co-authors 0
Gearoid M McMahon
Brigham and Women's Hospital, MA Harvard Medical School
Career Start Year 1999
Number of shared co-authors 7
Rajesh Mohandas
LSU Health New Orleans School of Medicine
Career Start Year 1999
Number of shared co-authors 0
Maja T Lindenmeyer
University Medical Center Hamburg-Eppendorf
Career Start Year 1998
Number of shared co-authors 15
Afshin Parsa
National Institute of Diabetes and Digestive and Kidney Diseases
Career Start Year 1996
Number of shared co-authors 15
Morgan E Grams
New York University Grossman School of Medicine
Career Start Year 1996
Number of shared co-authors 8
Mukut Sharma
Midwest Veterans' Biomedical Research Foundation, KCVA Medical Center
Career Start Year 1996
Number of shared co-authors 2
Hans-Joachim Anders
University Hospital of the Ludwig Maximilians University Munich
Career Start Year 1995
Number of shared co-authors 9
Sushrut S Waikar
Boston University Chobanian & Avedisian School of Medicine, Boston Medical Center
Career Start Year 1995
Number of shared co-authors 29
Jun Oh
Konyang University Hospital
Career Start Year 1993
Number of shared co-authors 8
Andrew A House
The Lilibeth Caberto Kidney Clinical Research Unit, Western University
Career Start Year 1993
Number of shared co-authors 5
Isaac E Stillman
Mount Sinai Hospital
Career Start Year 1992
Number of shared co-authors 4
Robert J Walker
University of Otago
Career Start Year 1991
Number of shared co-authors 0
Jonathan Himmelfarb
Kidney Research Institute and Division of Nephrology, University of Washington
Career Start Year 1990
Number of shared co-authors 19
Rakesh Malhotra
University of California San Diego
Career Start Year 1989
Number of shared co-authors 0
Julia B Lewis
Vanderbilt University Medical Center
Career Start Year 1988
Number of shared co-authors 1
Carsten A B??ger
Hospital Traunstein, University Hospital Regensburg
Career Start Year 1988
Number of shared co-authors 12
Somchai Eiam-Ong
Chulalongkorn University
Career Start Year 1988
Number of shared co-authors 0
Gerjan Navis
University Medical Center Groningen
Career Start Year 1983
Number of shared co-authors 10

Collaborators

James W Scholey
University Health Network, University of Toronto
Co-authored papers 48
David Z I Cherney
University Health Network, University of Toronto
Co-authored papers 28
Andrew M Herzenberg
University of Toronto
Co-authored papers 16
Vesta Lai
Toronto General Hospital (Y.L.
Co-authored papers 12
Matthias Kretzler
University of Michigan ann arbor
Co-authored papers 12
Rohan John
University of Toronto
Co-authored papers 11
Paul R Fortin
Centre de recherche du Centre hospitalier universitaire de Quebec-Universite Laval
Co-authored papers 10
Debbie S Gipson
University of Michigan ann arbor
Co-authored papers 10
Brad H Rovin
the Ohio State University Wexner Medical Center
Co-authored papers 9
John C Lieske
Mayo Clinic
Co-authored papers 9
Rahim Moineddin
University of Toronto
Co-authored papers 9
Joan E Wither
Schroeder Arthritis Institute, Krembil Research Institute, University Health Network
Co-authored papers 9
Vimal K Derebail
University of North Carolina at Chapel Hill
Co-authored papers 8
Sharon G Adler
Co-authored papers 8
Carolina Landolt-Marticorena
Krembil Research Institute, University Health Network
Co-authored papers 8
Judith A Miller
University of Toronto
Co-authored papers 8
Carmen Avila-Casado
University Health Network
Co-authored papers 8
Paul C Boutros
University of California los angeles
Co-authored papers 7
Murray B Urowitz
Schroeder Arthritis Institute, Krembil Research Institute, University Health Network
Co-authored papers 6
Dafna D Gladman
Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital
Co-authored papers 6
Jeffrey B Kopp
National Institutes of Health, National Institute of Diabetes
Co-authored papers 6
Stuart Yang
Toronto General Research Institute, University Health Network
Co-authored papers 5
Stephenie D Prokopec
University Health Network
Co-authored papers 5
Wendy Lou
Dalla Lana School of Public Health, University of Toronto
Co-authored papers 5
Bernard Zinman
Mount Sinai Hospital, University of Toronto
Co-authored papers 5
Laura Barisoni
Duke University
Co-authored papers 5
John Deanfield
Co-authored papers 4
Krzysztof Kiryluk
Columbia University
Co-authored papers 4
Jeffrey B Hodgin
University of Michigan ann arbor
Co-authored papers 4
David T Selewski
Medical University of South Carolina
Co-authored papers 4
Release 1.2